Literature DB >> 9152232

Murine orthotopic corneal transplantation in high-risk eyes. Rejection is dictated primarily by weak rather than strong alloantigens.

Y Sano1, B R Ksander, J W Streilein.   

Abstract

PURPOSE: Using a model of orthotopic corneal transplantation in which allografts were placed in normal eyes of mice, the authors previously reported that grafts bearing minor H antigens alone are more likely to be rejected (approximately 50%) than are grafts displaying only major histocompatibility (MHC) alloantigens (20%). These studies have been extended to include corneal grafts placed in neovascularized high-risk eyes of recipient mice.
METHODS: Neovascularization was induced by placing sutures in the central cornea of one eye of recipient mice. Two weeks later, MHC class I only, class II only, minor H only, or MHC+minor H disparate corneas were grafted into these sutured eyes, and their rejection rates were examined.
RESULTS: Although MHC+minor H disparate corneal allografts were rejected uniformly in neovascularized graft beds in 12 (100%) of 12, MHC class I only disparate grafts were rejected in 8 (66.7%) of 12 and MHC class II only disparate corneal allografts were rejected in 7 (58.3%) of 12. Surprisingly, the rejection rate of minor H only disparate corneal allografts was 10 (90.9%) of 11.
CONCLUSIONS: These findings indicate that for orthotopic corneal allografts placed in high-risk graft beds, minor H antigens offer a more formidable barrier to graft acceptance than do MHC-encoded antigens. The authors speculate that this unexpected outcome may reflect a reduced level of MHC expression on corneal tissue. Moreover, because the cornea as a graft lacks bone marrow-derived dendritic cells, allorecognition by recipient T cells must occur by way of the indirect pathway of alloantigen processing, and in this situation, minor H antigens may compete favorably with MHC antigens for presentation by recipient antigen-presenting cells that infiltrate the graft.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152232

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  14 in total

Review 1.  Immunologic privilege of the eye.

Authors:  J W Streilein
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  Severing corneal nerves in one eye induces sympathetic loss of immune privilege and promotes rejection of future corneal allografts placed in either eye.

Authors:  K J Paunicka; J Mellon; D Robertson; M Petroll; J R Brown; J Y Niederkorn
Journal:  Am J Transplant       Date:  2015-04-14       Impact factor: 8.086

4.  The resolvin D1 analogue controls maturation of dendritic cells and suppresses alloimmunity in corneal transplantation.

Authors:  Jing Hua; Yiping Jin; Yihe Chen; Takenori Inomata; HyunSoo Lee; Sunil K Chauhan; Nicos A Petasis; Charles N Serhan; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-08-21       Impact factor: 4.799

5.  Use of Post-transplant Cyclophosphamide Treatment to Build a Tolerance Platform to Prevent Liquid and Solid Organ Allograft Rejection.

Authors:  Casey O Lightbourn; Dietlinde Wolf; Sabrina N Copsel; Ying Wang; Brent J Pfeiffer; Henry Barreras; Cameron S Bader; Krishna V Komanduri; Victor L Perez; Robert B Levy
Journal:  Front Immunol       Date:  2021-03-02       Impact factor: 7.561

6.  Allergic conjunctivitis exacerbates corneal allograft rejection by activating Th1 and th2 alloimmune responses.

Authors:  Jerry Y Niederkorn; Peter W Chen; Jessamee Mellon; Christina Stevens; Elizabeth Mayhew
Journal:  J Immunol       Date:  2010-04-21       Impact factor: 5.422

7.  Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis).

Authors:  Reza Dana
Journal:  Trans Am Ophthalmol Soc       Date:  2007

8.  Allergic airway hyperreactivity increases the risk for corneal allograft rejection.

Authors:  J Y Niederkorn; P W Chen; J Mellon; C Stevens; E Mayhew
Journal:  Am J Transplant       Date:  2009-05       Impact factor: 8.086

9.  Azithromycin treatment increases survival of high-risk corneal allotransplants.

Authors:  Carlos A Medina; Alexander M Rowe; Hongmin Yun; Jared E Knickelbein; Kira L Lathrop; Robert L Hendricks
Journal:  Cornea       Date:  2013-05       Impact factor: 2.651

10.  Role of CCR7 in facilitating direct allosensitization and regulatory T-cell function in high-risk corneal transplantation.

Authors:  Yiping Jin; Sunil K Chauhan; Daniel R Saban; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-09-24       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.